drugset / Trial / NCT00557817
Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)
Phase 2/3
Completed
125 enrolled
University of Liege
Amgen · collabKU Leuven · collabVrije Universiteit Brussel · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Darbepoetin-alpha and i.v. iron administration after autologous hematopoietic stem cell transplantation for hematological malignancies : a prospective randomized trial.
Timeline
- Start
- 2004-03
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Darbepoetin alfa | Protein / enzyme biologic | 300 ug | Subcutaneous |
| Comparator | Iron sucrose | Unknown | 200 mg | Intravenous |
| Comparator | Iron sucrose | Unknown | 300 mg | Intravenous |